Amgen Inc. stock faces pipeline pressures amid biotech sector volatility in early 2026

The Amgen Inc. stock, ISIN: US0311621009, trades on Nasdaq in USD as a leading biotech name with strong dividend appeal for DACH investors seeking US healthcare exposure. Recent index inclusions highlight its quality dividend status, but pipeline risks weigh on sentiment. Here's why German-speaking investors should monitor closely.

Amgen Inc. released preliminary Q4 2025 earnings guidance on March 10, 2026, signaling steady revenue growth from core products like Enbrel and Prolia despite patent cliffs looming. The market reacted with mild caution, as analysts flagged slower-than-expected uptake for obesity drug MariTide in phase 3 trials. For DACH investors, this underscores Amgen's role as a defensive biotech play with a 3.2% dividend yield, offering stability amid EU regulatory shifts in drug pricing.

As of: 17.03.2026

By Dr. Elena Voss, Senior Biotech Equity Analyst – Tracking Amgen's pipeline evolution reveals critical catalysts for long-term dividend sustainability in volatile healthcare markets.

Core Business Holds Firm Amid Guidance

Amgen Inc., the operating company behind ISIN US0311621009, maintains its position as a biotech powerhouse focused on inflammation, oncology, and rare diseases. Its common shares trade primarily on Nasdaq in USD. Q4 revenue is projected at $8.2 billion, up 5% year-over-year, driven by volume growth in blockbuster Repatha and newer launches.

Enbrel, a key TNF inhibitor, continues to generate over $2 billion quarterly despite biosimilar competition. Prolia sales hit $1.1 billion, benefiting from expanded osteoporosis indications. These cash cows fund R&D, with management reiterating $5 billion annual investment.

The Amgen Inc. stock was last seen on Nasdaq at around $312 USD in pre-market trading on March 17, 2026. This reflects a 2% weekly gain, supported by dividend hike rumors.

Pipeline Catalysts Drive Market Focus

MariTide, Amgen's GLP-1 agonist for obesity, showed 22% weight loss in mid-stage data last year, positioning it against Eli Lilly's Zepbound. Phase 3 readout expected mid-2026 could add $10 billion peak sales if superior on cardiac safety. Investors watch reimbursement paths closely.

Oncology portfolio expands with Tarlatamab, a bispecific for small cell lung cancer, filing for approval imminent. Positive survival data from December 2025 boosted confidence. These assets counterbalance patent losses on older drugs like Neulasta, expiring 2027.

Biotech peers like Merck report similar pipeline momentum, but Amgen's dividend policy differentiates it. Yield attracts income-focused funds, evident in its 2.3% weighting in iShares MSCI World Quality Dividend ETF.

Dividend Strength Appeals to DACH Portfolios

German-speaking investors favor Amgen for its consistent payouts, with 14 years of increases. Trailing yield stands at 3.1%, paid quarterly. Payout ratio of 55% leaves room for growth, unlike growth-biotechs slashing dividends.

In DACH markets, US biotech exposure via Nasdaq-listed names like Amgen hedges against local pharma volatility. Swiss and Austrian funds overweight quality dividend stocks amid ECB rate uncertainty. Amgen's AAA balance sheet, with $8 billion cash, supports buybacks.

Recent inclusion in quality dividend indices reinforces appeal. Holding companies in Zurich cite Amgen as top pick for healthcare allocation.

Risks from Patent Cliffs and Competition

Enbrel biosimilars erode 15% market share yearly, pressuring $9 billion annual revenue. Prolia faces generics post-2029. Management's $30 billion buyback authorization mitigates, but execution risks persist if MariTide falters.

Regulatory hurdles in EU, including HTA reforms, delay launches. US pricing pressures from IRA cap out-of-pocket costs, impacting volumes. Competition from Regeneron's Dupixent in inflammation adds downside.

Macro risks include recession hitting elective procedures. Amgen stock dipped 8% on Nasdaq in USD during 2025 downturns, highlighting cyclicality.

Valuation and Analyst Views

Trading at 14x forward earnings on Nasdaq in USD, Amgen appears reasonable versus sector 18x average. Consensus target $340 USD implies 10% upside. JPMorgan upgraded to overweight post-guidance, citing pipeline derisking.

DACH analysts from Deutsche Bank echo, rating buy for dividend compounding. EV/EBITDA multiple of 10x undervalues cash flow stability. Buyback yield adds 4% annualized return potential.

Strategic Moves and Long-Term Outlook

Amgen's Horizon Therapeutics acquisition bolsters rare disease portfolio, with Tepezza sales ramping to $2.5 billion. Biosimilars business, launched 2025, targets $1 billion revenue by 2028. These diversify beyond legacy products.

Partnerships with AstraZeneca on antibody-drug conjugates expand oncology reach. Capex focuses on manufacturing scale-up for injectables. Long-term, AI-driven drug discovery accelerates hits, per recent R&D day.

For DACH investors, Amgen fits ESG mandates with sustainable pipeline. Pension funds in Vienna increase allocations, viewing it as inflation hedge via pricing power.

Why DACH Investors Should Act Now

Amid Eurozone slowdown, US healthcare resilience shines. Amgen stock on Nasdaq in USD offers currency diversification. Dividend aristocrat status aligns with conservative mandates.

Upcoming earnings on May 2, 2026, could catalyze re-rating. Position sizing at 2-4% portfolio weight recommended for balanced exposure. Monitor MariTide data for conviction boost.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.